Loading
Hormone-driven breast cancer can come back 10 or even 20 years after treatment, unlike most cancers, which is why hormone therapy lasts so long.
About half of recurrences in HR+ disease occur after year 5; risk continues at 1-2% per year to year 20 (EBCTCG, Pan 2017), driven by tumour size and nodal status. Motivates extended endocrine therapy (ATLAS, aTTom, MA.17), adjuvant CDK4/6 inhibitors for high-risk disease, and research into dormancy, ctDNA surveillance, and late-recurrence prediction assays (Breast Cancer Index).
Showing the technology this term belongs to: MRD / molecular residual disease testing.
Shares Disseminated tumour cells (DTCs), Anxiety around scans, and what the evidence says about how often to scan, What is not a second cancer: recurrence, metastasis and field cancerisation, Fear that the cancer will come back: how common it is, and when it stops being ordinary worry.
Shares Keep them asleep: dormancy maintenance as adjuvant therapy, What decides which disseminated cells ever colonise?, Disseminated tumour cells (DTCs), The pre-metastatic niche.
Shares Anxiety around scans, and what the evidence says about how often to scan, Fear that the cancer will come back: how common it is, and when it stops being ordinary worry, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer.
Shares Anxiety around scans, and what the evidence says about how often to scan, Fear that the cancer will come back: how common it is, and when it stops being ordinary worry, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer.
Shares Keep them asleep: dormancy maintenance as adjuvant therapy, What decides which disseminated cells ever colonise?, Tumour dormancy.
Shares Tumour dormancy, Dormant cells and minimal residual disease.
Shares Fear that the cancer will come back: how common it is, and when it stops being ordinary worry, Testicular germ cell tumours, Survivorship and late effects are neglected, HR-positive / HER2-negative breast cancer.
Shares Dormant cells and minimal residual disease, MRD / molecular residual disease testing, HR-positive / HER2-negative breast cancer.